Literature DB >> 8121860

Massive blood loss in trauma patients. The benefits and dangers of transfusion therapy.

G R Phillips1, D R Kauder, C W Schwab.   

Abstract

In acutely injured patients, recognition of profound shock may be difficult initially. Ensuring adequate oxygenation, restoring intravascular volume, and controlling ongoing blood loss are key principles of treatment in these patients. Additionally, an appreciation for and recognition of the possible adverse consequences of massive transfusion (ie, hypothermia, coagulopathy, hypocalcemia, hyperkalemia, and hemolysis) enable physicians to prevent them or at least lessen their effects.

Entities:  

Mesh:

Year:  1994        PMID: 8121860

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  4 in total

1.  Determinants of mortality in trauma patients following massive blood transfusion.

Authors:  Kanchana Rangarajan; Arulselvi Subramanian; Ravindra Mohan Pandey
Journal:  J Emerg Trauma Shock       Date:  2011-01

2.  Statistical Machines for Trauma Hospital Outcomes Research: Application to the PRospective, Observational, Multi-Center Major Trauma Transfusion (PROMMTT) Study.

Authors:  Sara E Moore; Anna Decker; Alan Hubbard; Rachael A Callcut; Erin E Fox; Deborah J Del Junco; John B Holcomb; Mohammad H Rahbar; Charles E Wade; Martin A Schreiber; Louis H Alarcon; Karen J Brasel; Eileen M Bulger; Bryan A Cotton; Peter Muskat; John G Myers; Herb A Phelan; Mitchell J Cohen
Journal:  PLoS One       Date:  2015-08-21       Impact factor: 3.240

3.  Analysis of the Blood Consumption for Surgical Programs.

Authors:  Dzenana Begic; Ermina Mujicic; Jozo Coric; Svjetlana Loga Zec; Lejla Zunic
Journal:  Med Arch       Date:  2016-07-27

4.  Moderate plasma dilution using artificial plasma expanders shifts the haemostatic balance to hypercoagulation.

Authors:  Elena I Sinauridze; Alexander S Gorbatenko; Elena A Seregina; Elena N Lipets; Fazoil I Ataullakhanov
Journal:  Sci Rep       Date:  2017-04-12       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.